1:34 PM
 | 
Apr 21, 2017
 |  BC Week In Review  |  Company News  |  Deals

Celgene, Antengene deal

Antengene gained rights in Taiwan and China, including Hong Kong and Macau, to oncology candidate CC-223 from Celgene. Celgene received an undisclosed equity stake in Antengene, and took a board seat. Antengene will be responsible for local development...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >